Perflubron

Summary

Perflubron (CHEMBL1200866) is an approved small-molecule radioopaque medium (ATC V08CX01); indicated across 1 condition including bronchopulmonary dysplasia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08CX01
• Indications: 1 condition
• Chemistry: 498.96 Da · C8BrF17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200866
Name	Perflubron
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9873
ChEBI	CHEBI:38803
ATC	V08CX01
Molecular formula	C8BrF17
Molecular weight	498.96
InChIKey	WTWWXOGTJWMJHI-UHFFFAOYSA-N

SMILES: C(C(C(C(C(F)(F)Br)(F)F)(F)F)(F)F)(C(C(C(F)(F)F)(F)F)(F)F)(F)F

IUPAC name: 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane

ChEBI definition: A haloalkane that is perfluorooctane in which a fluorine attached to one of the terminal carbons has been replaced by a bromine.

Pharmacological roles (ChEBI): radioopaque medium, blood substitute.

Also known as: Imagent, Liquivent, N-perfluorooctyl bromide, Perflubron, Perfluorocaprylyl bromide, Perfluoroctyl bromide, Perfluorooctylbromide, Pfob, SID29217975, PERFLUBRON, SID144205906, SID170465144

Patent coverage: 3,935 distinct patent families (14,373 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.15	Potency	707.9	nM	CHEMBL_ACT_3649226

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bronchopulmonary dysplasia	1	MONDO:0019091	MONDO:0019091

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).